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Background
Although Hodgkin’s lymphoma is a highly curable disease with modern chemotherapy proto-
cols, some patients are primary refractory or relapse after first-line chemotherapy or even after
high-dose therapy and autologous stem cell transplantation. We investigated the potential role
of allogeneic stem cell transplantation in this setting.
Design and Methods
In this phase II study 92 patients with relapsed Hodgkin’s lymphoma and an HLA-identical sib-
ling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated
with salvage chemotherapy followed by reduced intensity allogeneic transplantation. Fourteen
patients showed refractory disease and died from progressive lymphoma with a median overall
survival after trial entry of 10 months (range, 6-17). Seventy-eight patients proceeded to allo-
graft (unrelated donors, n=23). Fifty were allografted in complete or partial remission and 28 in
stable disease. Fludarabine (150 mg/m2 iv) and melphalan (140 mg/m2 iv) were used as the con-
ditioning regimen. Anti-thymocyte globulin was additionally used as graft-versus-host-disease
prophylaxis for recipients of grafts from unrelated donors.
Results
The non-relapse mortality rate was 8% at 100 days and 15% at 1 year. Relapse was the major
cause of failure. The progression-free survival rate was 47% at 1 year and 18% at 4 years from
trial entry. For the allografted population, the progression-free survival rate was 48% at 1 year
and 24% at 4 years. Chronic graft-versus-host disease was associated with a lower incidence of
relapse. Patients allografted in complete remission had a significantly better outcome. The over-
all survival rate was 71% at 1 year and 43% at 4 years. 
Conclusions
Allogeneic stem cell transplantation can result in long-term progression-free survival in heavily
pre-treated patients with Hodgkin’s lymphoma. The reduced intensity conditioning approach
significantly reduced non-relapse mortality; the high relapse rate represents the major remain-
ing challenge in this setting. The HDR-Allo trial was registered in the European Clinical Trials
Database (EUDRACT, https://eudract.ema.europa.eu/) with number 02-0036
Key words: allogeneic stem cell transplantation, reduced intensity conditioning, Hodgkin’s
lymphoma relapsed, refractory.
Citation: Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R,
Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ,García-Noblejas A, López Corral L, Xicoy
B, Sierra J, and Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in
patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a
prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea
(GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow
Transplantation. Haematologica 2012;97(2):310-317. doi:10.3324/haematol.2011.045757
©2012 Ferrata Storti Foundation. This is an open-access paper. 
Allogeneic stem cell transplantation after reduced intensity conditioning 
in patients with relapsed or refractory Hodgkin’s lymphoma. Results 
of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de
Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working
Party of the European Group for Blood and Marrow Transplantation
Anna Sureda,1,2 Carme Canals,3 Reyes Arranz,4 Dolores Caballero,5 Josep Maria Ribera,6 Mats Brune,7
Jacob Passweg,8 Rodrigo Martino,1 David Valcárcel,1 Joan Besalduch,9 Rafael Duarte,10 Angel León,11
Maria Jesus Pascual,12 Ana García-Noblejas,4 Lucia López Corral,5 Bianca Xicoy,6 Jordi Sierra,1 and Norbert Schmitz13
1Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 2Department of Haematology, Addenbrooke’s
Hospital, Cambridge, UK; 3EBMT Office, Barcelona, Spain; 4Hematology Department, Hospital de la Princesa, Madrid, Spain;
5Hematology Department, Hospital Clínico Universitario, Salamanca, Spain; 6Hematology Department, ICO-Hospital Germans 
Trias i Pujol, Badalona, Spain; 7Hematology Section, Sahlgrenska University Hospital, Göteborg, Sweden; 8Departement Medecine
Interne, Hopitaux Universitaires de Geneve, Geneve, Switzerland; 9Hematology Department, Hospital Son Dureta, Palma de
Mallorca, Spain; 10Institut Català d’Oncologia, L’Hospitalet de Llobregat, Spain; 11Hematology Department, Hospital de Jerez 
de la Frontera, Jerez de la Frontera, Spain; 12Hematology Department, Hospital Carlos Haya, Málaga, Spain, and
13Hematology/Oncology Department, Asklepios Klinik St. Georg, Hamburg, Germany
ABSTRACT
310 haematologica | 2012; 97(2)
Introduction
Hodgkin’s lymphoma (HL) is highly responsive to con-
ventional chemotherapy.1,2 Autologous stem cell trans-
plantation (ASCT) is the standard of care for patients with
relapsed HL.3,4 The results of ASCT vary significantly
depending on a number of prognostic factors.5-7 Only 20–
35% of patients with HL refractory to first-line therapy
currently go on to achieve long-term survival after ASCT.8-
10 For patients relapsing after ASCT the outcome is gener-
ally dismal. 
Registry data11,12 showed that allogeneic stem cell trans-
plantation (SCT) after myeloablative conditioning resulted
in lower relapse rates but significantly higher toxicity than
ASCT.13-14 Although the poor results after myeloablative
conditioning could be explained by the very poor-risk fea-
tures of many individuals included in these early trials, the
high non-relapse mortality (NRM) prevented the wide-
spread use of allogeneic SCT.  
Reduced-intensity conditioning (RIC) regimens would
appear particularly attractive for patients in need of allo-
geneic SCT. The literature contains several reports detail-
ing the outcomes of RIC transplants for patients with
relapsed HL.15-20 Compared to myeloablative conditioning
regimens, RIC has reduced NRM and improved overall
survival.21
In spite of the increasing evidence of a clinical benefit of
RIC-allogeneic SCT in patients with relapsed HL, many
questions remain. The Lymphoma Working Party (LWP)
of the European Group for Blood and Marrow
Transplantation (EBMT) together with the Grupo Español
de Linfomas/Trasplante Autólogo de Médula Ósea
(GEL/TAMO) undertook the largest multicenter phase 2
prospective clinical trial presented so far with the objec-
tive to analyze NRM and other major outcome parameters
after allogeneic SCT in relapsed HL.
Design and Methods
The HDR-Allo study protocol was approved by the LWP of the
EBMT, the GEL/TAMO steering group, by the ethics committees
of participating centers and registered in the European Clinical
Trials Database (EUDRACT, https://eudract.ema.europa.eu/) with
the number 02-0036. This was a prospective, multicenter phase 2
study in which ten European centers participated (Appendix 1).
The study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonization
Guidelines for Good Clinical Practice.
Eligibility and exclusion criteria 
Eligibility criteria included patients with biopsy proven classical
HL with primary refractory disease after two lines of chemother-
apy, relapses after first-line therapy with a short complete remis-
sion (<12 months), multiply relapsed patients and patients who
relapsed after an ASCT, aged between 18 and 65 years, Eastern
Cooperative Oncology Group (ECOG) performance status 0 to 2
unless impaired performance status was progressive disease-relat-
ed at the time of entry into the trial, adequate renal function
(serum creatinine <2 x upper limit of normal), hepatic function
(serum bilirubin <2 x upper limit of normal or alanine amino-
transaminase, aspartate aminotransaminase, alkaline phosphatase
<2 x upper limit of normal), cardiac function (left ventricle ejection
fraction >40%), and pulmonary function (DLCO >40%) and an
HLA identical sibling or a fully matched or one antigen mis-
matched (9 out of 10 antigens), unrelated donor. All patients were
required to provide written informed consent. 
Exclusion criteria included known positivity for human
immuno deficiency virus, other serious, uncontrolled medical con-
ditions, concurrent or previous malignancy, or pregnancy. 
Registration and end-points
Patients were centrally registered (Figure 1). Although patients
were registered before receiving salvage chemotherapy, the study
focused on patients able to proceed to allogeneic transplantation.
The primary end-point was NRM at 1 year post-transplant.
Secondary end-points were: NRM at day +100 post-transplanta-
tion, relapse rate, progression-free survival, overall survival, hema-
tologic and extra-hematologic toxicities, incidences of acute and
chronic graft-versus-host disease (GVHD), and evaluation of
chimerism after fludarabine-melphalan conditioning. On an inten-
tion-to-treat basis, progression-free and overall survival were also
calculated from trial entry in the whole population of patients.
Salvage therapy 
After trial registration, patients were treated with two courses
of salvage DHAP (dexamethasone 40 mg iv days 1-4; cytarabine 2
x 2000 mg/m2 iv over 3 h, day 2, bid; cisplatinum 100 mg/m2 iv
over 24 h, day 1) although other salvage protocols were allowed
by choice of the investigator depending on the salvage therapy
that the patient had received before. Only patients in complete
remission or with a partial response or stable disease after salvage
chemotherapy were allowed to continue on trial. 
Stem cell collection and conditioning regimen
Both bone marrow and peripheral blood were allowed as
sources of stem cells. Conditioning consisted of fludarabine 150
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Figure 1. Study design.
PD: progressive disease; CR: complete remission;
PR: partial remission; SD: stable disease; RIC-allo:
reduced intensity conditioning allogeneic stem cell
transplantation.
mg/m2 iv (from day -8 to day -4) and melphalan 140 mg/m2 iv
(from day -3 to day -2). Recipients of stem cells from matched
unrelated donors also received anti-thymocyte globulin 45 mg/kg
iv (from day -4 to day – 2).
Graft-versus-host disease prophylaxis
GVHD prophylaxis consisted of cyclosporine A at an initial
dose of 1.5 mg/kg bid iv from day -2 and a short course of
methotrexate at a dose of 10 mg/m2 iv on days +1, +3, +6 and +11.
In the absence of acute GVHD of grade 2 or more, cyclosporine A
was tapered down by 10% weekly starting on day +90 after the
RIC-allogeneic SCT and was discontinued by day +180 post-trans-
plantation.
Assessment of graft-versus-host disease and donor
chimerism 
The diagnosis of acute GVHD was based on the classical clinical
presentation with confirmatory pathological findings. Acute and
chronic GVHD were assessed and graded according to published
criteria.22,23 Chimerism was evaluated at day 21-28 after transplan-
tation and every 15 days thereafter until complete donor
chimerism of T cells was achieved. Complete donor chimerism
was defined as the presence of at least 95% donor DNA in the
sample analyzed.
Donor lymphocyte infusions
Patients who relapsed or progressed after allogeneic SCT were
eligible for donor lymphocyte infusions (DLI) in the absence of
GVHD grade 2 or more. Escalating doses of CD3-positive donor
lymphocytes (from 1¥107 to 5¥108 CD3+/kg body weight) were
given every 2 months if there was no evidence of GVHD and dis-
ease response. Patients with persistent mixed donor chimerism
were also eligible for DLI. 
Definitions and response criteria
Patients were staged according to the Ann Arbor system24 and
evaluated by means of computed tomographic scans and gallium67
gammagraphy. Patients were clinically staged at protocol entry,
after salvage chemotherapy, on day +90 after transplantation,
every 6 months for the first 2 years, and then yearly or as clinically
indicated. Patients who received DLI for disease relapse or pro-
gression were also evaluated 1 month after the infusions. Patients
who survived more than 90 days after RIC-allogeneic SCT with-
out evidence of tumor were classified as having a complete
response. Relapse after RIC-allogeneic SCT was histologically
confirmed when possible. Disease response was evaluated accord-
ing to Cheson’s criteria.25 For the purposes of this study, those
patients allografted in complete or partial remission were consid-
ered as chemosensitive patients while those allografted in stable
disease were considered chemorefractory.
Sample size calculation and statistical analysis
To determine the main end-point, NRM at 1 year after trans-
plantation, to a precision of ± 10% (95% confidence interval), 80
transplanted patients were necessary (expected NRM at 1 year of
40%). Taking into account the expected percentage of patients
who would not be transplanted because of no response to salvage
chemotherapy, 132 patients needed to be included. The first
patient was included in April 2000 and 92 patients had been
recruited by August 2007. At that time the trial was prematurely
closed by the steering committee because of the low patient
recruitment. The database was closed and the final statistical
analysis performed as of August 2009.
Data were analyzed according to previously published guide-
lines.26,27 Time-to-event outcomes with competing risks (NRM,
relapse incidence and GVHD) were estimated as cumulative inci-
dence curves. NRM was calculated from the date of transplanta-
tion until death from causes other than relapse whenever it
occurred. Actuarial curves were estimated for progression-free and
overall survival (measured from transplantation until progression
or death from any cause) according to the Kaplan-Meier method.
Overall and progression-free survival were also calculated from
trial entry in the whole population of patients. The log-rank test
was used to compare survival curves in univariate analyses. Any P
values less than or equal to 0.05 were defined as statistically sig-
nificant. Potential prognostic factors for overall survival, progres-
sion-free survival, relapse incidence and NRM were evaluated in
multivariate analyses by using Cox proportional hazards regres-
sion. Cumulative incidences were calculated using NCSS97 soft-
ware (NCSS, Kaysville, UT, USA). All other computations were
a. sureda et al.
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Table 1. Clinical characteristics of the patients at diagnosis and
before entering the HDR-Allo protocol (n=92).
Measurement
Sex
Males 51 (55%)
Females 41 (45%)
Age [median (range)] in years at diagnosis 28 (13-54)
Histology subtype at diagnosis
Nodular sclerosis 50 (54%)
Mixed cellularity 20 (22%)
Lymphocyte rich 17 (18%)
Lymphocyte depletion 5 (6%)
Clinical characteristics at diagnosis
Ann Arbor stage III-IV   59 (64%)
B symptoms  39 (42%)
Bone marrow involvement  8 (9%)
Bulky disease 31 (34%)
Clinical characteristics at entry into the trial
Ann Arbor stage III-IV   70 (79%)
B symptoms  47 (53%)
Bone marrow involvement  18 (20%)
Bulky disease  35 (40%)
Diagnosis – entry in the trial [median (range)], months 41 (6-295)
> 2 lines of therapy  83 (90%)
Prior radiotherapy 80 (87%)
Prior ASCT 79 (86%)
Time to progression from allogeneic SCT 
[median (range)] in months 8 (12-144)
< 12 months 55 (70%)
Salvage therapy before RIC-allogeneic SCT
GEMOX 45 (58%)
ESHAP/DHAP 23 (30%)
ICE 6 (8%)
Others 4 (4%)
Reason for entering the HDR-Allo trial
Primary refractory disease 2 (2%)
Relapse after a short 1st complete remission 3 (4%)
Multiple relapses 7 (8%)
Failure of a prior ASCT 76 (86%)
ASCT: autologous stem cell transplantation; RIC: reduced intensity conditioning; SCT:
stem cell transplantation; DHAP: dexamethasone, cisplatin, cytarabine; ESHAP: etopo-
side, cisplatin, cytarabine, prednisone; GEMOX: gemcitabine, oxaliplatin; ICE: ifosfamide,
carboplatin, etoposide.
performed using the SPSS 15.0 statistical package (SPSS, Chicago,
IL, USA). All P values were two-sided.
Results
The patients’ characteristics are presented in Table 1.
Fifty-one males and 41 females with a median age at diag-
nosis of 28 (13 – 54) years were included.  Most patients
had received more than two lines of therapy (90%), prior
radiotherapy (87%) and a previous ASCT had failed (86%).
The median number of cycles of salvage chemotherapy
before undergoing RIC-allogeneic SCT was two (range, 2
to 3). Fourteen patients (15%) progressed under salvage
therapy and were excluded from further study treatment.
None of these patients received an allograft and were only
considered candidates for palliative treatment. The median
overall survival of these patients was 10 (6–17) months; all
of them died from disease progression.
Seventy-eight patients (85%) went on to RIC-allogeneic
SCT (Table 2). Fifty patients (67%) were allografted with
chemosensitive disease (i.e. they were in complete or par-
tial remission) and 28 (33%) with chemoresistant disease
(i.e. the patients had stable disease). Ten patients (13%)
had an ECOG score of 2 or more. A matched sibling donor
was used in 55 procedures (70%). The median follow up
of the surviving patients was 48 months (range, 24–84).
Non-relapse morbidity and mortality and engraftment
Ten patients died before day +100 from transplant-relat-
ed causes: two from interstitial pneumonitis, four from
infectious episodes, three from multi-organ failure and
one from a pulmonary hemorrhage. Eight additional
patients died from transplant-related causes without evi-
dence of disease: two from bacterial infections, two from
invasive aspergillosis, three from chronic GVHD and one
patient from an Epstein-Barr virus-positive post-transplant
lymphoproliferative disorder. The cumulative incidence of
NRM was 8% (95%CI, 6–11) at 100 days, 15% (95%CI,
13–17) at 1 year, and 17% (95%CI, 15–19) at 2 years
(Figure 2A). Age over 45 years at the time of RIC-allogene-
ic SCT, poor performance status and refractory disease
were significantly associated with a higher NRM (P=0.05,
P=0.05 and P=0.01, respectively) (Table 3). 
All patients experienced complete hematologic recovery
after RIC-allogeneic SCT. The median time to achieve
more than 0.5¥109/L neutrophils in the peripheral blood
was 13 days (range, 10–18) days after transplantation; a
sustained platelet count greater than 20¥109/L was
achieved at 14 days (range, 10–35, 3 patients did not reach
this count by the time of death) after transplantation. Of
note and as opposed to what has been seen with
Campath-containing strategies, all patients were full
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Table 2. Characteristics of the patients at RIC-allogeneic SCT.
Measurement
Dx – RIC-Allo [median (range)] in months 46 (9-300)
Disease status at RIC-allo
Sensitive disease (CR, PR) 50 (67%)
CR 20 (40%)
PR 30 (60%)
Refractory disease (SD) 28 (33%)
ECOG ≥ 2 at RIC-allo (%) 10 (13%)
Donor age [median (range)] in years 36 (18-63)
Donor sex
Male 37 (47%)
Female 41 (53%)
Donor-recipient sex matching 
Donor (M) – Receptor (F) 21 (27%)
Donor (M) – Receptor (M) 16 (20%)
Donor (F) – Receptor (F) 25 (32%)
Donor (F) – Receptor (M) 16 (21%)
CMV status (donor and receptor)
Both negative 8 (10%)
Other combinations 70 (90%)
Type of donor
Matched sibling donor 55 (70%)
Matched unrelated donor 23 (30%)
Stem cell source 
Bone marrow 3 (4%)
Peripheral blood 75 (96%)
Dx: diagnosis; RIC-allo. reduced intensity conditioning allogeneic stem cell transplanta-
tion; CR: complete remission; PR: partial remission; SD: stable disease; M: male; F:
female; CMV: cytomegalovirus.
Figure 2. (A) Non-relapse mortality of the allografted patients. (B)
Relapse incidence. (C) Impact of disease chemosensitivity on
relapse incidence.
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donor chimeras at day +28 after RIC-allogeneic SCT. The
most important extra-hematologic toxicity seen in the
early post-transplant period was oral mucositis, with 40%
of our series having grade 3 or more oral mucositis.
Incidence of acute and chronic graft-versus-host 
disease
Among 73 patients at risk, 35 patients (48%) developed
acute GVHD. It was grade 2 or more in 11 patients (15%).
The median time to develop acute GVHD was 36 days
(range, 21–63). The cumulative incidence of acute GVHD
at day +100 was 32% (94%CI 28–36). The development
of acute GVHD was not associated with a decreased
relapse incidence after transplantation, but a non-signifi-
cant increase in NRM was observed.
Among 68 patients at risk, 32 patients (47%) developed
chronic GVHD, which was extensive in 15 patients (46%).
The median time to develop chronic GVHD was 187 days
(range, 100–424) after RIC-allogeneic SCT. Six-month, 1-
year and 2-year cumulative incidences of chronic GVHD
were 30% (95%CI, 24–34), 40% (95%CI 37–44) and 44%
(95% 41–47), respectively. Chronic GVHD was analyzed
as a time-dependent variable and was associated with a
significantly lower relapse incidence after RIC-allogeneic
transplantation (P=0.04) (Figure 3). A significant improve-
ment in progression-free survival was also found in
patients developing chronic GVHD (P=0.05).
Relapse incidence
Forty (51%) patients have relapsed at a median of 6
months after RIC-allogeneic SCT (range, 3-35 months).
The cumulative incidence of relapse was 37% (95%CI,
34–40) at 1 year and 59% (95%CI, 55–63) at 4 years
(Figure 2B). The strongest predictor of relapse was refrac-
tory disease [HR 2.0 (1.6–3.0), P=0.01] (Figure 2C, Table 3). 
Donor lymphocyte infusions
Twenty patients (50% of the relapsed patients) received
DLI for relapse or progressive disease after RIC-allogeneic
SCT; nine patients had cytoreductive therapy before DLI.
The median number of DLI received per patient was three
(range, 2–4) and the median time from the allogeneic pro-
cedure to the first DLI was 6 months (range, 4–12). The
median number of CD3+ lymphocytes infused was 0.5¥108
CD3+ cells/kg (range, 1¥107 – 1¥108). The response rate
(complete and partial responses) was 40% in those patients
receiving DLI alone (3 complete responses and 3 partial
responses in 11 patients) and 53% (3 complete responses
and 2 partial responses) for those patients receiving addi-
tional chemotherapy. None of the five patients achieving a
partial remission after DLI showed a continuous remission;
the median time to progression was 7 months (range, 3–
12). None of the complete remissions achieved after DLI
with or without chemotherapy was long-lasting. All
patients suffered from a disease relapse at a median time of
13 months (range, 12–15) after the last infusion.
Progression-free survival
The estimated progression-free survival rate from trial
entry for the 92 patients was 48% (95%CI, 43–52) at 1
year and 18% (95%CI, 15–21) at 4 years (Figure 4A). For
the allografted population, 22 patients remain alive and
progression-free since RIC-allogeneic SCT after a median
follow up of 32 months (range, 12–71). The estimated pro-
gression-free survival rate for the allografted population
was 48% (95%CI, 44–52) at 1 year and 24% (95%CI, 22–
27) at 4 years (Figure 4B). Chemosensitivity was the most
important prognostic factor (HR = 2.3; 95%CI, 1.3–3.1;
P=0.001) (Figure 4C) (Table 3). Patients allografted in com-
plete remission had the best outcome, with progression-
free survival rates at 1 and 4 years of 70% (95%CI 67–73)
and 50% (95%CI 47–53), respectively (data not shown).
The type of donor did not have any influence on progres-
sion-free survival after RIC-allogeneic SCT.
Overall survival
The estimated overall survival rate from trial entry was
64% (95%CI, 60–69) at 1 year and 41% (95%CI, 37–45)
at 4 years (Figure 4D). In the allografted population and
after a median follow-up for the surviving patients of 48
months (range, 24–82), 33 patients were alive (43%) and
45 had died (57%). The estimated overall survival rate was
71% (95%CI, 67–76) and 43% (95%CI, 39–46) at 1 and 4
years, respectively (Figure 4E). Refractory disease (Figure
4F) and a poor performance status were associated with a
significantly worse overall survival (HR 1.9, 95%CI 1.0–
2.7, P=0.001 and HR 2.5, 95%CI 1.3–4.2, P=0.01, respec-
tively) (Table 3). The fact of having a matched unrelated
donor rather than a related donor did not have a signifi-
cant impact on overall survival either.
a. sureda et al.
314 haematologica | 2012; 97(2)
Table 3. Multivariate analysis of the four major outcomes.
HR 95%CI P value
Non-relapse mortality
Age > 45 years 2.1 1.0-4.5 0.05
ECOG score ≥ 2 3.4 1.6-7.6 0.05
Refractory disease 2.8 1.8-4.6 0.01
Relapse incidence
Refractory disease 2.0 1.6-3.0 0.01
Progression-free survival
ECOG score ≥ 2 1.8 1.5-3.2 0.01
Refractory disease 2.3 1.3-3.1 0.001
Overall survival
ECOG score ≥ 2 2.5 1.3-4.2 0.01
Refractory disease 1.9 1.0-2.7 0.001
HR: hazard ratio; CI. confidence interval.
Figure 3. Impact of the development of chronic GVHD on relapse
incidence after transplantation.
0 12 24 36 48 60
Time from RIC-allo (months)
No chronic GVHD (n=35)
chronic GVHD (n=32)
P=0.04
1.0
0.8
0.6
0.4
0.2
0
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
)
Discussion
In spite of early data showing promisingly low relapse
rates after allogeneic transplantation, the transplantation
community was not very enthusiastic about considering
allogeneic SCT for HL patients because of the exceedingly
high NRM.11,12 The advent of RIC regimens was most wel-
come to overcome the problem by reducing NRM while,
it was hoped, preserving the beneficial effect of the
donor’s alloreactive T cells infused with the graft. In addi-
tion, it has been demonstrated that better supportive care
has significantly improved the results of allogeneic SCT
over time.28
Retrospective analyses of the EBMT LWP demonstrated
that a reduction in NRM had been achieved.21
Nevertheless and in spite of the increasing number of HL
patients allografted over the last 15 years, published stud-
ies do have important limitations, such as the small num-
bers of patients included, the use of different conditioning
regimens and GVHD prophylaxis, and the relatively short
follow up. In addition, all studies were retrospective in
nature with selection biases and other confounding fac-
tors.  
Of note, this is the largest prospective clinical trial look-
ing at the outcome of patients with relapsed HL treated
with a RIC allograft both in terms of numbers of patient
included and follow up. Unfortunately, despite the fact
that the trial was actively recruiting for several years, it
finally had to be closed because of poor accrual of
patients. This fact as well as the year when the trial was
opened justifies some of its potential pitfalls: Positron
emission tomography scanning was not included as a
method to assess disease response to therapy and poten-
tial co-morbidities of the patients were more strictly con-
sidered. Although this prospective trial was to have
included four different subgroups of patients, the vast
majority (86%) were enrolled because a prior autograft
had failed. Keeping this in mind, a NRM of 15% at 1 year
looks very promising. NRM was adversely influenced by
older age, poor performance score and, most importantly,
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Figure 4. (A) Progression-free survival (PFS)
from entry into the trial. (B) Progression-free
survival of the allografted population. (C)
Impact of disease chemosensitivity on progres-
sion-free survival. (D) Overall survival from
entry into the trial. (E) Overall survival (OS) of
the allografted population. (F) Impact of dis-
ease chemosensitivity on overall survival.
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by the presence of refractory disease, an observation in
line with registry data published by the EBMT.19
Disease relapse or progression represents the major
cause of failure. The cumulative incidence of relapse was
59% at 3 years; it was significantly higher in patients with
resistant disease. These figures are in agreement with
those published by other groups.15,17,18,20 Chemoresistant
patients with HL should not offered allogeneic SCT – at
least with the protocol we used. These patients might
benefit from more aggressive conditioning and/or chang-
ing the GVHD prophylaxis.29
The progression-free survival rate was 48% (95%CI,
44–52) at 1 year and 24% (95%CI, 22–27) at 4 years for
the allografted population. The figures are significantly
better for patients allografted with chemosensitive disease
and particularly for patients allografted in complete remis-
sion. Accordingly, more emphasis should be laid on
achievement of complete remission prior to transplanta-
tion. 
There is no evidence that the use of a matched unrelated
donor impaired the outcome of the procedure as has been
extensively indicated by others.30 If a patient is considered
a candidate for an allogeneic procedure and does not have
a matched sibling donor, a search for a matched unrelated
donor should be started immediately.
The lower NRM associated with the use of RIC proto-
cols allows the detection of a clinically meaningful graft-
versus-HL effect. Chronic GVHD was associated with a
significantly lower relapse incidence after transplantation.
This has also been shown by the two registry analyses of
the LWP of the EBMT19,21 and also by the Spanish series.18
The low incidence of relapse translated into a significant
improvement of progression-free survival after the proce-
dure. Indirect evidence of a graft-versus-HL effect may be
the plateau seen in both the progression-free and overall
survival curves after 3 years. Finally, we and others
observed significant responses to DLI although we, in con-
trast to the UK Cooperative Group,17 were unable to find
durable remissions after DLI.
In spite of the increasing number of HL patients being
allografted there is no agreement among investigators
about who should be offered an allogeneic SCT. Two ret-
rospective analyses including HL patients who relapsed
after an ASCT31,32 seem to indicate that for those patients
with a HLA compatible donor and who are able to reach
the transplant procedure, consolidation with a RIC-allo-
geneic SCT offers a better long-term outcome than the use
of conventional strategies. In our trial, none of the 14
patients not transplanted because of insufficient response
to salvage chemotherapy was alive at the time of this
analysis. Taking into account the results of this study, one
might think that better salvage strategies should be inves-
tigated in order to try increase the percentage of patients
demonstrating chemosensitivity. The introduction of so-
called ‘new drugs’ (e.g. brentuximab vedotin) in the relapse
setting could eventually help to improve this percentage.  
Even with the results of this prospective study many
questions remain to be answered. The best conditioning
protocol is unknown, although information from registry
analyses indicates that the intensity of the conditioning
regimen matters. In children and adolescents, the use of
myeloablative protocols was not associated with higher
NRM but significantly reduced the relapse incidence as
compared to RIC protocols29 The use of low dose total
body irradiation (2 Gy) seems to be associated with a
higher incidence of relapse and a lower progression-free
survival.16,19 Accordingly, enforcing the debulking of the
tumor by adding further drugs or otherwise strengthening
the anti-tumor effect may help to reduce the relapse rates
after allogeneic SCT. In this sense, a tandem ASCT – RIC-
allogeneic SCT approach has been tested by several
authors31 in those patients with highly refractory HL.
ASCT would be used as “debulking therapy” in order to
render to the patient chemosensitive to the last line of
treatment and take advantage of the allogeneic effect in a
second step. A better selection of patients may be another
aspect. Positron emission tomography may help to deter-
mine the most suitable group.32 The emerging concept of
maintenance with new drugs after ASCT could eventually
be transported to the allogeneic field and, finally, the allo-
geneic procedure might be moved forwards in the thera-
peutic strategy of HL and tested in those relapsed patients
in whom a poor outcome after ASCT is anticipated.
In summary, the results of this prospective clinical trial
emphasize the role of RIC-allogeneic SCT in patients with
relapsed HL after ASCT. The plateau phase in the survival
curve of those patients allografted in complete remission
supports the existence of a clinically beneficial graft-versus-
HL effect. Major efforts should be made to bring patients
to an allogeneic procedure, as the results of other therapies
seem to be significantly worse, and to reduce the still too
high relapse incidence after it.
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